Skip to main content

Table 4 Serum biochemical outcomes after atorvastatin treatment or placebo

From: Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial

Variables Baseline 8 weeks Treatment difference,
atorvastatin minus
placebo (95% CI)
  Atorvastatin
(n = 35)
Placebo
(n = 32)
Atorvastatin & ICS
(n = 32)
Placebo &ICS
(n = 25)
 
Total cholesterol
(mmol/l)
5.15
(0.89)
5.67
(1.12)
3.62
(0.76)
5.34
(0.90)
-1.55
(-1.88, -1.23)
P < 0.0001
Triglycerides
(mmol/l)
1.59
(0.87)
2.18
(1.41)
1.02
(0.35)
1.74
(1.29)
-0.49
(-0.87, -0.11)
P = 0.013
LDL-cholesterol
(mmol/l)
3.19
(0.82)
3.49
(0.99)
1.89
(0.62)
3.46
(0.87)
-1.50
(-1.88, -1.13)
P < 0.0001
HDL-cholesterol
(mmol/l)
1.24
(0.35)
1.26
(0.31)
1.29
(0.35)
1.23
(0.27)
0.03
(-0.06, 0.13)
p = 0.497
Alkaline phosphatase
(IU/l)
83.33
(31.36)
75.16
(21.04)
98.62
(91.26)
77.16
(19.58)
5.94
(-15.67, 27.54)
p = 0.584
ALT
(IU/l)
17.58
(9.27)
22.50
(11.88)
22.00
(14.37)
24.04
(11.70)
3.67
(-1.84, 9.18)
p = 0.188
  1. Abbreviations: ALT, alanine aminotransferase
  2. Data represented as mean (SD).